Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0Y8OW)

Drug Name
N,N-dimethylarginine Drug Info
Synonyms
N,N-dimethylarginine; ADMA; Asymmetric dimethylarginine; 30315-93-6; Dimethyl-L-arginine; NG,NG-dimethyl-L-arginine; N(G)-Dimethylarginine; Guanidino-N,N-dimethylarginine; N(G),N(G)-Dimethylarginine; (S)-2-Amino-5-(3,3-dimethylguanidino)pentanoic acid; N(G1),N(G1)-Dimethylarginine; Lopac-D-4268; N(5)-((Dimethylamino)iminomethyl)-L-ornithine; N(omega),N(omega)-dimethyl-L-arginine; NG,NG-DIMETHYLARGININE HYDROCHLORIDE; CHEBI:17929; YDGMGEXADBMOMJ-LURJTMIESA-N; N5-[(Dimethylamino)iminomethyl]-L-ornithine
Cross-matching ID
PubChem CID
123831
ChEBI ID
CHEMBL17929
CAS Number
CAS 30315-93-6
TTD Drug ID
D02DQQ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Dilated cardiomyopathy 1.86 3.79e-2 86/96 (89.58%) ITGA4;TPM2;TGFB1;...
Bladder cancer -1.61 4.69e-2 40/41 (97.56%) MMP1;CDK4;HBEGF;...
Endometrial cancer -1.61 4.73e-2 56/58 (96.55%) BAX;CASP9;CTNNA1;...
Bacterial invasion of epithelial cells -1.62 4.90e-2 59/77 (76.62%) ARPC2;ELMO1;ARPC5;...
Pentose phosphate pathway -1.62 4.70e-2 25/30 (83.33%) FBP1;TKT;GPI;...
Retinol metabolism -1.63 4.74e-2 41/68 (60.29%) ALDH1A3;CYP2C9;CYP1A2;...
Amoebiasis -1.64 4.57e-2 99/102 (97.06%) SERPINB10;LAMB3;PRKCA;...
Mitophagy -1.64 4.60e-2 56/68 (82.35%) USP8;AMBRA1;ATF4;...
Small cell lung cancer -1.66 4.24e-2 90/92 (97.83%) TP53;GADD45G;MAX;...
Vibrio cholerae infection -1.67 3.84e-2 44/50 (88%) KCNQ1;ATP6V0A2;ADCY3;...
Notch signaling pathway -1.68 3.40e-2 49/59 (83.05%) NOTCH3;ADAM17;CIR1;...
NF-kappa B signaling pathway -1.69 3.45e-2 90/104 (86.54%) BCL10;CSNK2A2;TNFSF11;...
Necroptosis -1.69 3.50e-2 113/159 (71.07%) GLUD2;IL1B;CYLD;...
Histidine metabolism -1.70 3.41e-2 16/22 (72.73%) ASPA;ALDH9A1;CNDP2;...
p53 signaling pathway -1.71 3.47e-2 63/73 (86.3%) CDK2;CYCS;CASP8;...
Butanoate metabolism -1.72 3.19e-2 23/28 (82.14%) EHHADH;ECHS1;GAD1;...
Basal cell carcinoma -1.74 3.06e-2 41/63 (65.08%) BMP4;FZD5;BAX;...
Metabolism of xenobiotics by cytochrome P450 -1.77 2.62e-2 49/77 (63.64%) GSTM4;CYP2C9;SULT2A1;...
Tryptophan metabolism -1.79 2.52e-2 35/42 (83.33%) CYP1B1;DHTKD1;ACAT2;...
Primary bile acid biosynthesis -1.79 2.75e-2 15/17 (88.24%) CYP39A1;BAAT;AMACR;...
Glycolysis / Gluconeogenesis -1.81 1.89e-2 56/67 (83.58%) HK2;ALDOC;PGM1;...
Legionellosis -1.82 1.96e-2 51/57 (89.47%) SAR1A;CYCS;ARF1;...
Kaposi sarcoma-associated herpesvirus infection -1.82 1.58e-2 172/193 (89.12%) NRAS;ICAM1;JUN;...
Epithelial cell signaling in Helicobacter pylori infect... -1.85 1.44e-2 62/70 (88.57%) JUN;CHUK;ADAM17;...
Rheumatoid arthritis -1.87 8.40e-3 78/93 (83.87%) IL1B;IL23A;CSF1;...
Thyroid cancer -1.96 5.04e-3 36/37 (97.3%) TPR;TP53;GADD45G;...
NOD-like receptor signaling pathway -1.97 3.15e-3 145/181 (80.11%) ERBIN;HSP90AB1;CASP8;...
Lipid and atherosclerosis -2.01 4.20e-3 190/215 (88.37%) CASP6;SELP;MAP3K5;...
TNF signaling pathway -2.11 0.00e+0 103/112 (91.96%) CSF1;CXCL6;MAP3K5;...
IL-17 signaling pathway -2.42 0.00e+0 84/94 (89.36%) HSP90AB1;ELAVL1;CASP8;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 2.22uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 2.22uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.03uM - 2.22uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 2.22uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H